Atlas company financials

BIO-TECHNE Corp

Standardized 17-year financial series for BIO-TECHNE Corp, built from filing-derived source data and exposed in JSON, CSV, and XLSX so it can feed iterFact artifacts or analyst workflows without hand-entering the numbers.

United StatesCIK 0000842023FY2009 → FY2025

Open JSON Download CSV Download XLSX Quarterly JSON Summary JSON Filing index

Latest fiscal year

FY2025

Revenue

$1.2B

Adjusted EBITDA

—

Net result

$73.4M

Net financial debt

—

Latest source: FY2025 filing · published data snapshot generated April 26, 2026

Phase 2 summary

Latest quarter, TTM, and growth are now pre-computed for chat and templates.

Latest quarter revenue

$295.9M

TTM revenue

$1.2B

TTM free cash flow

—

Latest quarter net result

$38M

Quarterly coverage: 50 periods · latest quarter FY2025-Q2 · TTM revenue growth 4.7%.

What this gives you

A proof-of-concept company data surface, not a dead PDF shelf.

The same standardized payload behind this page is exposed through downloadable CSV and XLSX files plus a stable JSON route. That makes it usable as a live input to iterFact templates, a spreadsheet handoff, or a future API surface without re-normalizing the source documents again.

Source audit

Official links first, raw iterFact payloads right next to them.

Official sources

SEC EDGAR companyfacts
comparative · bio-techne-corp-fy2009 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2011-08-29 · Retrieved: 2026-04-26T11:49:20.594765+00:00
SEC EDGAR companyfacts
primary · bio-techne-corp-fy2012 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2012-08-29 · Retrieved: 2026-04-26T11:49:20.594765+00:00
SEC EDGAR companyfacts
primary · bio-techne-corp-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2013-08-29 · Retrieved: 2026-04-26T11:49:20.594765+00:00
SEC EDGAR companyfacts
us-gaap:InterestExpense · us gaap companyfacts · comparative · bio-techne-corp-fy2013 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2015-08-31 · Retrieved: 2026-04-26T11:49:20.594765+00:00
SEC EDGAR companyfacts
primary · bio-techne-corp-fy2014 · Attribution: U.S. Securities and Exchange Commission EDGAR filings and companyfacts data. · Release: 2014-08-29 · Retrieved: 2026-04-26T11:49:20.594765+00:00

Ten-year series

Headline company financials by fiscal year

Fiscal year	Revenue	Adj. EBITDA	EBIT	Net result	Op. cash flow	Capex	Net debt	Status
FY2009	264M	—	151M	105M	111M	-7M	—	comparative annual fact carried from later 10k · missing accounts receivable · missing adjusted ebitda · missing current assets · missing current liabilities · missing interest expense · missing inventory · missing net financial debt · missing research and development
FY2010	269M	—	156M	110M	111M	-5M	—	comparative annual fact carried from later 10k · missing adjusted ebitda · missing interest expense · missing net financial debt · missing research and development
FY2011	290M	—	163M	112M	127M	-4M	—	missing adjusted ebitda · missing interest expense · missing net financial debt · missing research and development
FY2012	315M	—	166M	112M	127M	-6M	—	missing adjusted ebitda · missing interest expense · missing net financial debt · missing research and development
FY2013	311M	—	158M	113M	124M	-22M	—	missing adjusted ebitda · missing net financial debt · missing research and development
FY2014	358M	—	160M	111M	137M	-14M	—	missing adjusted ebitda · missing net financial debt · missing research and development
FY2015	452M	—	147K	108M	139M	-20M	—	missing adjusted ebitda · missing net financial debt · missing research and development
FY2016	499M	—	151M	104M	144M	-17M	—	missing adjusted ebitda · missing net financial debt · missing research and development

Filing provenance